Technology
Health
Pharmaceutical

Marinus Pharmaceuticals

$4.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.17 (4.05%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell MRNS and other stocks, options, ETFs, and crypto commission-free!

About

Marinus Pharmaceuticals, Inc. Common Stock, also called Marinus Pharmaceuticals, is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Read More Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

Employees
28
Headquarters
Radnor, Pennsylvania
Founded
2003
Market Cap
220.73M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
856.97K
High Today
$4.49
Low Today
$4.16
Open Price
$4.24
Volume
210.24K
52 Week High
$10.54
52 Week Low
$2.36

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
Therapy
Medical
2014 IPO
US

News

Yahoo FinanceApr 26

How Much Of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Do Institutions Own?

750

Earnings

-$0.27
-$0.23
-$0.19
-$0.15
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.